Research: The Road to the Cure
The Westchester Brain Tumor Program is deeply engaged in three types of research:
1. Clinical trials – late-stage trials of carefully researched and tested methods of care.
2. Basic science research – examining brain tumor pathologies and developing innovative therapy starting in the laboratory.
3. Translational research – applying research to develop actual treatment protocols for clinical use.
- DCVax®-L Vaccine
- HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM (HeatShock)
- Rindopepimut (CDX-110) Vaccine
- Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Clinical Trials for Pediatrics
The Westchester Brain Tumor Program is currently seeking promising clinical trials for pediatric brain tumor treatment.
For more information about clinical trials at Westchester Brain Tumor Program, call (914) 948-3008 or email us at email@example.com.
Basic Science Research
John M. Abrahams, M.D., Director of the Westchester Brain Tumor Program, is researching the use of hydrogel materials as a topical agent to be used after surgical resection to assist in destroying residual tumor cells, which can lead to a reoccurrence of the tumor. This project involves a biocompatible hydrogel that targets the tumor-brain interface and works on destroying the malignant tumor cells after the wound is closed. The hydrogel delivers a chemotherapy agent to do the work; the hydrogel keeps the chemotherapy in the proper location.
The Westchester Brain Tumor Program is currently developing protocols for recurrent Glioblastoma Multiforme (GBM). Please check periodically for updates within this program.